Malaria Clinical Trial
Official title:
Novel Use Of Hydroxyurea in an African Region With Malaria
Multiple studies have shown that hydroxyurea has clinical efficacy in preventing acute
painful episodes and reducing the need for blood transfusions in children with sickle cell
anemia (SCA), but no study has been conducted in malaria endemic regions of sub-Saharan
Africa, the areas with the most children with SCA.
The primary goal of this study is to investigate the safety and efficacy of hydroxyurea for
children with SCA in a malaria endemic region within sub-Saharan Africa.
The risk of malaria and hematologic toxicities from hydroxyurea in children with SCA living
in malaria endemic regions is unknown.
Some changes associated with hydroxyurea treatment (increased nitric oxide and HbF) would be
expected to protect against malaria, but the data on hydroxyurea-related endothelial changes
thought to be important in malaria pathogenesis (e.g. intracellular adhesion molecule
(ICAM)-1, von Willebrand factor (VWF), tumor necrosis factor (TNF)-α) is unclear, with some
studies suggesting that these factors might be increased with hydroxyurea and others
suggesting no difference or a decrease.
The specific aims of this study are as follows:
1. Determine the incidence of malaria in children with sickle cell anemia treated with
hydroxyurea vs. placebo
2. Establish the frequency of hematologic toxicities and adverse events in children with
sickle cell anemia treated with hydroxyurea vs. placebo
3. Define the relationship between hydroxyurea treatment and fetal hemoglobin (HbF),
soluble ICAM-1 (sICAM-1) and nitric oxide (NO) levels, and between levels of these
factors and risk of subsequent malaria.
Two hundred children from the Mulago Hospital Sickle Cell Clinic (MHSCC) in Kampala, Uganda
will be randomized to receive either hydroxyurea (100) or placebo (100) at a fixed dose of 20
± 2.5 mg/kg/day. The primary study endpoints will be evaluated after twelve months of study
treatment. After twelve months of study treatment, children will enter a follow-up phase
during which they can receive an additional twelve months of open-label hydroxyurea treatment
if they/their parents wish to do so after consultation with local physicians at the MHSCC.
The working hypotheses of this research study are:
1. The incidence of malaria is not greater in children with SCA treated with hydroxyurea
than those treated with placebo
2. Children with SCA treated with hydroxyurea will have more medication-related hematologic
toxicities, such as neutropenia, but no increase in SCA-related adverse events (e.g.
pain crises, hospitalizations, requirement for blood transfusion) compared to children
treated with placebo
3. Hydroxyurea will increase HbF and plasma NO levels and decrease plasma sICAM-1 levels;
HbF and plasma NO levels will inversely correlate, and plasma sICAM-1 levels will
positively correlate, with subsequent malaria incidence
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04601714 -
Baseline Cohort Malaria Morbidity Study
|
||
Withdrawn |
NCT04020653 -
A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria
|
Phase 2 | |
Terminated |
NCT04368910 -
Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria
|
Phase 3 | |
Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
Completed |
NCT02544048 -
Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
|
||
Completed |
NCT00527163 -
Role of Nitric Oxide in Malaria
|
||
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Active, not recruiting |
NCT04704674 -
Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
|
||
Completed |
NCT03276962 -
Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age
|
Phase 2 | |
Completed |
NCT04966871 -
Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults
|
Phase 1 | |
Completed |
NCT00289185 -
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants
|
Phase 2 | |
Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
Active, not recruiting |
NCT06153862 -
Africa Ready Malaria Screening
|
N/A | |
Completed |
NCT04545905 -
Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
|
||
Recruiting |
NCT06278181 -
Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
|
||
Withdrawn |
NCT02793388 -
A Trial on Supervised Primaquine Use in Ethiopia
|
Phase 4 | |
Completed |
NCT02909712 -
Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania
|
Phase 2 | |
Withdrawn |
NCT02793414 -
Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
|
||
Completed |
NCT02793622 -
Prevention of Malaria in HIV-uninfected Pregnant Women and Infants
|
Phase 3 | |
Completed |
NCT02605720 -
Cardiac Safety of Repeated Doses of Dihydroartemisinin-Piperaquine for the Use in Mass Treatment Campaigns
|
Phase 3 |